Cph Group Ag Class A · SIX:CPHN
Cph Group Ag Class A — FY2025 Earnings Presentation
39 slides from Cph Group Ag Class A's earnings presentation, Feb 18, 2026
Slide 1: Full Year 2025 results
A global industrial leader in attractive specialty chemicals niches and in pharmaceutical packaging Full Year 2025 results Media and Investors' Conference February 18, 2026
Slide 2: Disclaimer
Disclaimer Investing in the shares of CPH Group AG involves risks. Prospective investors are urged to consult their investment advisors and tax advisors prior to investing in CPH Group AG shares. This document contains forward-looking statements which involve risks and uncertainties. These statement
Slide 3: Agenda
Agenda Highlights Business Financial Strategy 2025 development results and Outlook Peter Schaub Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 3
Slide 4: 2025 in brief
2025 in brief First full financial year Strategic acquisitions Strong profitable of CPH Group without the at Zeochem (high-value growth of chromatography spun-off paper division chromatography gels) and gels and deuterated Perlen Packaging (vials products segments and containers) strengthen product
Slide 5: Agenda
Agenda Highlights Business Financial Strategy 2025 development results and Outlook Peter Schaub Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 5
Slide 6: Key figures 2025 at a glance
Key figures 2025 at a glance Sales EBITDA EBITDA margin in CHF million in CHF million in % 334 (2024: 323) 50 (2024: 54) 15 (2024: 17) Net result Free cash flow Equity ratio in CHF million in CHF million in % 23 (2024: 34) 16 (2024: 35) 55 (2024: 63) CPH Group Media and Investors' Conference of 18 F
Slide 7: CPH is a global industrial leader in specialty chemicals niches and pharmaceutical packaging
CPH is a global industrial leader in attractive specialty chemicals niches and in pharmaceutical packaging Zeochem Perlen Packaging 115 24 Key figures for 2025 in CHF million 219 26 Sales EBITDA Sales EBITDA Differentiation through high customer benefit Focused growth strategy Differentiation throug
Slide 8: Strong global megatrends and focused strategies drive growth
Strong global megatrends and focused strategies drive growth Megatrends Markets Applications Products Division Sales share Pharmaceutical Medicines packaging Health & Respirators Demography Pharmaceuticals Medical oxygen Molecular sieves 76% Chromatography gels API Deuterated products Natural gas/LN
Slide 9: Zeochem
Zeochem CPH Group Media and Investors' Conference of 18 February 2026 9
Slide 10: Zeochem – strategic highlights 2025
Zeochem – strategic highlights 2025 Focus on high-value specialties in global niche markets Louisville Québec Paris Zvornik Donghai 1979 2025 2025 2018 2016 o Highly valuable acquisition of SiliCycle, a global leader in pharma-grade chromatography gels based in Canada o Integration of SiliCycle enab
Slide 11: Zeochem: New record EBITDA and improved EBITDA margin
Zeochem New record EBITDA and improved EBITDA margin SALES Market environment CAGR 4.8% 140 o Stable market for applications of deuterated compounds and 120 chromatography gels; deuterated compounds with profitable 100 annual sales growth averaging 21% over the last five years 80 o Economic uncertai
Slide 12: Perlen Packaging
Perlen Packaging CPH Group Media and Investors' Conference of 18 February 2026 12
Slide 13: Perlen Packaging – strategic highlights 2025
Perlen Packaging – strategic highlights 2025 Specialist for pharmaceutical packaging Whippany Müllheim Tököl Suzhou 2006 2007 2025 2016 o Strategic portfolio expansion into complementary primary pharmaceutical packaging o LOG Pharma is an established pharma and medical packaging manufacturer with si
Slide 14: Perlen Packaging: Acquisition-driven growth, temporary decline in profitability
Perlen Packaging Acquisition-driven growth – but a temporary decline in profitability SALES Market environment CAGR 6.5% 250 o New capacities in Europe and sluggish economic environment 200 put pressure on volumes and prices o Raw material prices declined slightly 150 o Higher energy and transportat
Slide 15: Agenda
Agenda Highlights Business Financial Strategy 2025 development results and Outlook Peter Schaub Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 15
Slide 16: Key figures CPH Group
Key figures CPH Group 1 76% of sales from health market Sales Sales by region Sales by application in CHF million in CHF million in CHF million CAGR 5.9% 400 400 400 300 300 300 200 200 200 100 100 100 0 0 0 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Europe The Americ
Slide 17: Consolidated Income Statement I
2025 Financial Year Consolidated Income Statement I 1 Net sales 3.3% above prior-year, thereof +8.1% from acquisitions and -3.8% due to FX. Organic decline in particular due to geopolitical in CHF millions 2025 % 2024 1 % ± ±% uncertainties and lower raw material prices, Net sales 1 334.1 100.0 323.
Slide 18: Consolidated Income Statement II
2025 Financial Year Consolidated Income Statement II 1 Depreciation and amortization above prior year as a consequence of the Sorbchem, LOG Pharma and SiliCycle acquisitions. in CHF millions 2025 % 2024 1 % ± ±% 2 EBIT margin further down than EBITDA margin EBITDA 50.3 15.0 53.8 16.6 -3.5 -6.5% due
Slide 19: Consolidated Balance Sheet
2025 Financial Year Consolidated Balance Sheet 1 Increase in total assets by CHF 36.3 million, in CHF millions 31.12.2025 % 31.12.2024 % ± ±% CHF 48.7 million from acquisitions. Cash and cash equivalents 27.0 7.3 31.6 9.5 Trade receivables 56.5 15.3 48.3 14.5 2 Financial liabilities increased by CHF
Slide 20: Consolidated Cash Flow Statement
2025 Financial Year Consolidated Cash Flow Statement in CHF millions 2025 % 2024 1 % ± ±% 1 Non-cash items include depreciation and Net result 23.4 7.0 34.4 10.7 -11.0 -32.0% amortization and change in provisions. Non-cash items 1 19.1 5.7 8.5 2.6 2 Cash flow before change in net working capital at
Slide 21: Segment Results
2025 Financial Year Segment Results Zeochem Perlen Packaging CPH Group in CHF millions 2025 2024 ±% 2025 2024 ±% 2025 2024 1 ±% Net sales 1 114.7 117.3 -2.2% 4 219.4 206.0 +6.5% 334.1 323.3 +3.3% EBITDA 2 23.9 22.8 +4.5% 5 25.9 33.3 -22.2% 50.3 53.8 -6.5% EBITDA margin 20.8% 19.5% 11.8% 16.1% 15.0%
Slide 22: Sustainable corporate management
Sustainable corporate management Progress in implementing sustainability strategy Sustainable value Net-zero strategy Circular economy & creation o Striving for net zero innovation o Long-term corporate o Preparing an appropriate o Expanding circular purpose embedded stage plan, while portfolio o As
Slide 23: Agenda
Agenda Highlights Business Financial Strategy 2025 development results and Outlook Peter Schaub Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 23
Slide 24: Strategy and Outlook: A solid basis for an attractive investment case
Strategy and Outlook A solid basis for an attractive investment case Among the top 3 in Taking profit of Continuous Proven M&A and Strong balance attractive niche the global expansion of market integration skills sheet and highly markets with above megatrends position with a focus to widening offeri
Slide 25: Main growth initiatives to exploit sales and margin potential
Strategy and Outlook Main growth initiatives to exploit sales and margin potential Sales push Strengthening of sales organizations in attractive niche markets Innovation Widening of product portfolio to meet customer needs and create value Capacity utilization Increasing capacity utilization worldwi
Slide 26: Outlook 2026: Back to profitable growth in both divisions
Outlook 2026 Back to profitable growth in both divisions CPH Group o Market conditions volatile and challenging o Long-term megatrends of health & demography and energy intact o Stronger portfolio and footprint in high-value specialties in global niche markets and exploiting synergies in packaging o
Slide 27: Mid-term financial targets unchanged
Strategy and Outlook Mid-term financial targets unchanged Growth Profitability Cash flow Financing Dividend Sales EBITDA Free cash Equity Payout increase margins flow margins1 ratio ratio 5-8% p.a. 16-18% 8-10% >50% 25-50% 1 before acquisition of subsidiaries CPH Group Media and Investors' Conferenc
Slide 28: Q&A
Q&A CPH Group Media and Investors' Conference of 18 February 2026 28
Slide 29: Information for shareholders
Information for shareholders Market capitalisation as of 31.12.2025 Share price development in CHF million in CHF 415 100 80 60 6 million registered shares of 40 20 CHF 0.15 nominal value 0 2021 2022 2023 2024 2025 SPIX adjusted SPIX_adjusted CPHN1 CPHN_rebased 1 adjusted for the indicative share of
Slide 30: Calendar and contacts
Calendar and contacts Calendar Analysts 17.03.2026 Baader Helvea Annual General Meeting, Lucerne Volker Bosse Contacts 21.07.2026 Research Dynamics Publication of 2026 Half-Year Report Alexandre Müller Alois Waldburg-Zeil CEO +41 41 455 87 67 10.09.2026 Research Partners CPH Group Investors‘ Day in
Slide 31: Business locations worldwide
Business locations worldwide Consistent and ongoing internationalization over the last 15 years Müllheim 2007 Tököl 2025 2010 2025 Donghai Louisville Whippany Zvornik Louisville Whippany 2016 1979 2006 2018 1979 2006 Suzhou Müllheim Québec 2016 2007 2025 Perlen 1954 Perlen 1954 Anápolis Vadodara 201
Slide 32: Zeochem – top global niche player in specialty chemicals
Zeochem – top global niche player in specialty chemicals Leading market position backed by global megatrends Louisville Québec Zvornik Donghai 1979 2025 2018 2016 Key figures 2025 Employees (in CHF million) 452 Sales 115 Global presence close to 5yrs CAGR 4.8% customers o 6 production sites EBITDA o
Slide 33: Zeochem product portfolio
Zeochem Product portfolio improves quality of life and enables energy transition Molecular Chromatography Deuterated sieves gels products o Molecular sieves are used in o Highly porous gels for molecular o Hydrogen atom in different removing unwanted molecules and separation for use in the molecules
Slide 34: Molecular sieves for industrial applications
Zeochem Moleculars sieves for industrial applications Market overview Industries Global fragmented market o Pharmaceuticals with growth o Electronics o Petrochemistry 2-3% p.a. 1 o Manufacturing industries (glass, steel) o Automotive industry o Construction industry Strategic directions Segment mole
Slide 35: Chromatography gels for pharmaceuticals
Zeochem Chromatography gels for pharmaceuticals Market overview Industries Global fragmented market o Pharmaceuticals with growth o Biopharmaceuticals o Academia & Universities 5-10% p.a. 1 o Food & Beverage industry o Cosmetics Strategic directions Segment chromatography gels o Develop potential of
Slide 36: Deuterated products for pharmaceuticals and electronics
Zeochem Deuterated products for pharmaceuticals and electronics Market overview Industries Global fragmented market o Pharmaceuticals with growth o Electronics o Basic research 10% p.a. 1 Strategic directions Segment deuterated products o Focus on innovation CHF 100-150 million 1 o Increased product
Slide 37: Perlen Packaging – a true global player
Perlen Packaging – a true global player Unique position in pharmaceutical packaging Whippany Müllheim Tököl Suzhou 2006 2007 2025 2016 Key figures 2025 Employees (in CHF million) 784 Sales 219 Global presence close to 5yrs CAGR 6.5% customers o 7 production sites EBITDA o 11 distributors and agents
Slide 38: Pharmaceutical packaging with best protection for medicines
Perlen Packaging Pharmaceutical packaging with best protection for medicines Barrier effect Films for tablet blisters Up to 2x 50x better* better* Effectiveness of Effectiveness of water vapour oxygen barrier barrier Bottles and containers Up to 4x 100x 100x Up to 4x better* better* better* better*
Slide 39: Global pharmaceutical blister and bottle markets
Perlen Packaging No. 1 worldwide in highest barrier blister1 Global pharmaceutical market Largest markets Global pharmaceutical Global pharmaceutical outlook 20262 blister market: bottle market: o 1: USA CHF 2 billion 1 CHF 8 billion1 o 2: China Growth: Growth: Strategic directions o 3: Germany 3-6%